Artwork

Innhold levert av Clinical Care Options LLC and Clinical Care Options. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Clinical Care Options LLC and Clinical Care Options eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

Expert Discussions: Novel Agents Targeting Residual Inflammatory Risk in ASCVD and CKD

15:28
 
Del
 

Manage episode 436382945 series 3242427
Innhold levert av Clinical Care Options LLC and Clinical Care Options. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Clinical Care Options LLC and Clinical Care Options eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they discuss new and emerging therapies designed to target residual inflammatory risk associated with ASCVD and CKD.  

 Episode outline:  

  • Colchicine: inhibition of NLRP3 inflammasome assembly/activation
  • Canakinumab (anti–IL-1β monoclonal antibody)
  • Ziltivekimab (anti–IL-6 monoclonal antibody)
  • Other emerging targets/therapies

To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:  

  continue reading

36 episoder

Artwork
iconDel
 
Manage episode 436382945 series 3242427
Innhold levert av Clinical Care Options LLC and Clinical Care Options. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Clinical Care Options LLC and Clinical Care Options eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they discuss new and emerging therapies designed to target residual inflammatory risk associated with ASCVD and CKD.  

 Episode outline:  

  • Colchicine: inhibition of NLRP3 inflammasome assembly/activation
  • Canakinumab (anti–IL-1β monoclonal antibody)
  • Ziltivekimab (anti–IL-6 monoclonal antibody)
  • Other emerging targets/therapies

To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:  

  continue reading

36 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2025 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett
Lytt til dette showet mens du utforsker
Spill